Current recommendations are to screen for antiphospholipid antibodies in women with three
losses before 10 weeks or two losses after 10 weeks. 2, 6 Although recent evidence now …

Empson et al1 performed the Herculean task of reviewing 575 studies of therapy for
antiphospholipid antibody–associated pregnancy loss. Only ten of those studies fulfilled …

The presence of antiphospholipid antibodies has been associated with an increased risk of
recurrent pregnancy loss, and there is evidence to suggest that antithrombotic therapy …

The reported prevalence of antiphospholipid antibodies in women with a chief complaint of
pregnancy loss varies, as does the risk of adverse outcomes in subsequent pregnancies …

We read with great interest the article by Bates et al 1 in an issue of CHEST (February 2012),
in which the authors evaluate the evidence on the risk of pregnancy complications in women …

Well-established evidence exists that antiphospholipid antibody is causally associated with
complications during pregnancy, such as thromboembolism, preeclampsia, intrauterine …

OBJECTIVE: The present study was aimed at a comprehensive analysis of acquired
thrombophilia in a large series of Indian women with fetal loss. STUDY DESIGN: Four …

• Factor V Leiden: 3.7% to 26.5%• Prothrombin gene mutation: 0 to 10.8%• Protein S
deficiency: 0.7% to 24.7%• MTHFR variant: 6.7% to 24.0% A meta-analysis of all case …

Three decades ago, antiphospholipid antibodies (aPL) were proposed to have a causal
association with recurrent pregnancy loss (RPL), suspected because of placental clots that …

Background: Women with antiphospholipid antibodies (aPL) have a significant risk of
reproductive failure and adverse pregnancy outcomes, the recurrent miscarriages …